Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
eltrombopag
pediatric hematopoietic stem cell transplantation
thrombocytopenia
thrombopoietin receptor agonists
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
12
2019
revised:
16
01
2020
accepted:
17
01
2020
pubmed:
18
2
2020
medline:
14
7
2020
entrez:
18
2
2020
Statut:
ppublish
Résumé
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). While the use of thrombopoietin receptor agonists was retrospectively investigated in adults, data in pediatric posttransplant thrombocytopenia are lacking. We evaluated the safety and efficacy of eltrombopag in nine children with platelet transfusion-dependent persistent thrombocytopenia after HSCT. Eltrombopag was started at a median of 147 days after allo-SCT and continued for a median period of 64 days, the starting dose being 50 mg per day. The therapy was well tolerated. After a median time of treatment of 36 days, eight patients (88%) reached sustained platelets count >50 000/μL.
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
eltrombopag
S56D65XJ9G
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28208Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood. 1985;65:368-374.
Bruno B, Gooley T, Sullivan KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:154-162.
Yamazaki R, Kuwana M, Mori T, et al. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006;38(5):377-384.
Dodds A. Hematologic complications. In: Atkinson K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation. 2nd ed. Cambridge: Cambridge University Press; 2000:1038-1043.
Yamazaki R, Kuwana M, Mori T, et al. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006;38(5):377-384.
Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Eng J Med. 2007;357:2237-2247.
Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315-e325.
Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658.
Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Eng J Med. 2017;376:1540-1550.
Tanaka T, Inamoto Y, Yamashita T, et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(5):919-924.
Bosch-Vilaseca A, García-Cadenas I, Roldán E, et al. Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation. Eur J Haematol. 2018;101(3):407-414.
Yuan C, Boyd AM, Nelson J, et al. Eltrombopag for the treatment of thrombocytopenia post-allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1320-1324.
Bento L, Bastida JM, García-Cadenas I, et al. Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019;25(9):1825-1831.
Li S, Wu R, Wang B, et al. Eltrombopag for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation in children. J Pediatr Hematol Oncol. 2019;41(1):38-41.
Ali S, Gassas A, Kirby-Allen M, Krueger J, Ali M, Schechter T. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children. Pediatr Transplant. 2017;21(6). https://doi.org/10.1111/petr.13017
Naithani R, Sachdev M, Uttam R. Successful use of eltrombopag in a child with hurler syndrome after haploidentical hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2016;38(2):163-164.